The iPhone effect in healthcare: How Mounjaro is rewriting the economics of India’s pharma market

Mounjaro became India’s top-selling drug because demand for GLP-1 medicines has grown far beyond traditional generic categories. Patients are paying premium prices for treatments linked to diabetes, obesity and metabolic health. This marks a shift from a market where low-cost, high-volume medicines usually dominated sales.

Eli Lilly launched Mounjaro in India in March 2025. It recorded ₹923 crore in sales during 2025-26 and about ₹1,736 crore in the following 12 months to September 2026. Its rise reflects strong interest in newer therapies, injectable delivery systems and the promise of better outcomes.

Affordability still matters, but it is no longer the only choice factor. Brand reputation and confidence in a medicine matter more when treatment requires months of dose adjustment and patient responses vary. Mounjaro’s performance suggests Indian drugmakers may need to build trusted brands and treatment experiences, not only cheaper products.

GLP-1 drugs are medicines that act like the body’s GLP-1 hormone, helping regulate blood sugar and appetite. They are used in diabetes treatment and, under medical supervision, for obesity and weight management. The article presents them as part of a wider shift toward treating obesity as a chronic disease rather than only a lifestyle issue.

Most GLP-1 medicines are injected under the skin of the abdomen, thigh or upper arm. Pill-based options also exist. Their use often involves gradual dose increases, called titration, over several months. Individual responses can differ, so doctors guide treatment and monitor patients.

The category has expanded beyond diabetes into metabolic health and weight loss. India has an estimated 101 million people with diabetes and 254 million living with obesity, although not all are candidates for GLP-1 treatment. These medicines do not replace diet, exercise or medical supervision.

India’s GLP-1 market is expanding rapidly. It was worth ₹2,596 crore in the 12 months to September 2026, according to Pharmarack data. Analyst Vishal Manchanda estimated the market could be running at an annualised rate close to ₹3,000 crore, suggesting the reported total is still an early measure of demand.

Injectables dominate the category, accounting for about 86% of market value. Mounjaro alone recorded about ₹1,736 crore in sales over the same 12-month period. Semaglutide sales also accelerated after Indian companies launched generic versions following Novo Nordisk’s patent expiry in March 2026.

Monthly semaglutide sales rose from ₹48 crore in February to ₹113 crore in September 2026. Unit sales jumped from about 114,000 to 1,876,000. Generics made up nearly 74% of units sold. Their lower prices widened access, even though monthly treatment still cost ₹1,850 to ₹8,000.

Semaglutide volumes surged because generic versions entered the market after Novo Nordisk’s patent expired in March 2026. Several Indian companies launched competing products, increasing supply and giving patients more choices. Competition reduced the entry barrier even though the medicines remained expensive by Indian pharmaceutical standards.

Monthly sales climbed from ₹48 crore in February 2026 to ₹113 crore in September. Unit sales increased nearly sixteen times, from about 114,000 to 1,876,000. Generics accounted for nearly 74% of those units. Their monthly treatment prices ranged from ₹1,850 to ₹8,000, depending on the product and regimen.

The increase shows that affordability is relative, not absolute. A medicine can remain costly while becoming more reachable than a patented alternative. Rising awareness of obesity and diabetes also created demand. Brand confidence still shaped choices, but generic entry expanded the number of people able to try semaglutide.

Brand reputation matters because patients and doctors often cannot judge a medicine’s effectiveness immediately. GLP-1 treatment involves gradual dose increases, and people respond differently. In that uncertain setting, a trusted brand can become a practical signal of quality, reliability and expected results.

The article describes patients comparing generic semaglutide with Mounjaro, even when the active treatment may produce similar weight loss. One user reported losing only 300 grams in a week on a generic and was advised to consider Mounjaro instead. The recommendation reflected the brand’s perceived superiority, not necessarily a proven difference in that individual case.

Delivery systems also shape the treatment experience. Most GLP-1 drugs use injections, while pills offer another format. Companies that combine credible branding, convenient delivery and confidence in outcomes may command premium prices. This gives Indian manufacturers an opportunity to compete through treatment experiences, not only low prices.

A drug patent is a legal right that gives a company temporary exclusivity over an invention, such as a new medicine. This protection limits competitors from selling the same patented product during the patent term. It helps the original company recover the cost and risk of developing the treatment.

When the patent expires, the exclusive barrier ends. Other companies can then produce versions with the same active ingredient, subject to regulatory requirements. These products are called generics. They usually compete through lower prices because several manufacturers can enter the market rather than one company controlling supply.

The article gives semaglutide as the example. Novo Nordisk’s patent expired in March 2026, after which several Indian companies launched generic versions. Monthly unit sales rose from about 114,000 in February to 1,876,000 in September. Generic semaglutide made up nearly 74% of units sold.

Indian pharmaceutical companies have traditionally competed by making medicines affordable and selling them at large volumes. Premium GLP-1 medicines challenge that model. Patients are showing a willingness to pay more for newer therapies, trusted brands, convenient delivery and the possibility of better outcomes.

Mounjaro’s sales illustrate the opportunity. Launched in March 2025, it generated ₹923 crore in 2025-26 and about ₹1,736 crore in the following 12 months to September 2026. Generic semaglutide also expanded rapidly, proving that lower-priced products can grow the market while brands continue to influence patient choices.

Future competition may therefore involve more than manufacturing efficiently. Companies could invest in recognizable brands, doctor confidence, delivery systems and patient support. The article presents GLP-1 drugs as an early sign of this transition. Affordability will remain crucial, but it may no longer determine success by itself.